Journal of Bioequivalence & Bioavailability is the best open access journal that aims to publish most complete and reliable source of information on the discoveries and advanced developments in this field in the form of original articles, review articles, case reports, short communications, etc. and provide free online access to it without any restrictions or any other subscriptions to researchers worldwide. Journal of Bioequivalence & Bioavailability is one of the best Open Access journals of Scholarly publishing.

Anti-diabetes drugs are a kind of drugs that lower abnormally high levels of glucose in the blood, a characteristic of endocrine disorders known as diabetes mellitus. Anti-diabetes drugs are medicines designed to stabilize and control blood sugar levels in diabetics. Anti-diabetes drugs are often used to treat diabetes. There are various types of anti-diabetes drugs such as insulin, pramlintide (amylin), GLP1 receptor agonists (such as Vietta and Victorosa), and oral hypoglycemic agents (tablets). Type I diabetes is a condition in which the body does not produce insulin. Therefore, insulin is the only treatment effective for type 1 diabetes. Injected insulin acts just like naturally occurring insulin to lower blood glucose levels. Type 2 diabetes initially has insulin resistance, this happens when the cells of the body do not respond to insulin in the same way as people without diabetes. Oral antidiabetic agents work in various ways to reduce blood sugar levels in people with type 2 diabetes, some stimulate insulin secretion by the pancreas, and others improve the responsiveness of cells to insulin or prevent glucose production by the liver. Others slow the absorption of glucose after meals. Many people with type 2 diabetes ultimately need insulin to control their high blood sugar levels. Each class of medicine has one or more medicines. Some of these drugs are taken orally, while others require injections. Drugs included older standbys such as metformin and insulin, and sulfonylurea drugs such as glipizide (glucotrol) and glimepiride (amalyl). Other studies have considered newer and more expensive classes, including thiazolidinediones such as pioglitazone (Actos) and rosiglitazone (Avandia). DPP inhibitors such as sitagliptin (Januvia) and saxagliptin (Onglyza). Many studies tested only a single drug, but more than 100 studies used the drug in combination with metformin. Overall, it is found that metformin worked as well as or better than other drugs in lowering blood sugar levels. When it comes to preventing complications and prolonging people's lifespan, a single drug or drugs combination was unnoticeable. Diabetes is a complex chronic disease associated with hyperglycemia or a hyperglycemic condition caused by a deficiency of insulin secretion, action, or both. Chronic metabolic imbalances associated with this disease increase the risk of long-term macro vascular and micro vascular complications in patients and, if not managed with quality care, the risk of Cardiovascular Disease (CVD). Causes frequent hospitalizations and complications, including increased.

Submit Manuscript: https://www.walshmedicalmedia.com/submissions/bioequivalence-bioavailability.html

Instructions for Authors: https://www.walshmedicalmedia.com/bioequivalence-bioavailability/instructionsforauthors.html